Company intelligence / Profile preview

Nume

Ownership: Private
Development stage: Other

Overview

Nume delivers AI-powered, genetics-based healthcare solutions focused on chronic conditions such as weight management, mental health issues like ADHD, and hormonal imbalances. The company uses advanced genetic testing to inform individualized treatment plans that combine medical interventions with lifestyle and nutrition guidance. Its telehealth model enables broad access across Australia, New Zealand, and Polynesia. Historical US entity "NuMe Health" developed cobiotic/prebiotic therapies targeting metabolic diseases before rebranding as MicroBiome Therapeutics.

Therapeutic areas: PsychiatryEndocrinologyMetabolic Disorders
Modalities: Genetic testingBiotechnology-based diagnostics and interventionsprebiotic/cobiotic products
Industry: Molecular Diagnostics

Partnerships

Pennington Biomedical Research Center (historical)

Beyond the preview

Go deeper on Nume.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nume.

Explore the full profile